| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
Lung cancer and pulmonary fibrosis is a progressive and lethal lung disease characterized by the accumulation of extracellular matrix, loss of pulmonary function, and change in lung structure. In this study, the delivery efficiency after intrapulmonary administration of nanoparticles to mice with metastatic lung tumor and bleomycin-induced pulmonary fibrosis. The anti-tumor siRNA-containing nanoparticles for intrapulmonary administration had tumor-cell specificity and delivery efficiency effectively silenced the oncogenes in the lung metastasis. Aerosolized PEGylated liposomes were efficiently delivered to fibrotic legions. This study suggests that aerosol-based novel nanoparticles are a new therapeutic strategy.
|
